HER-2/neu Amplification Testing in Breast Cancer by Multiplex Ligation-Dependent Probe Amplification in Comparison with Immunohistochemistry and In Situ Hybridization

Background: Assessment of HER-2/neu status in invasive breast cancer is crucial to establish eligibility for trastuzumab and taxane based chemotherapy. Next to immunohistochemistry (IHC) to evaluate protein overexpression, a second line gene amplification test is required for cases with equivocal protein expression. This study aimed to validate a new PCR based test, called Multiplex Ligation-dependent Probe Amplification (MLPA), as a simple and quick method to assess HER-2/neu gene amplification status in invasive breast cancer. Methods: MPLA results were compared with gene amplification status assessed by fluorescence in situ hybridization (FISH) and chromogenic in situ hybridization (CISH) as gold standard, and with protein overexpression by IHC in 518 breast carcinoma patients. Results: About 10% of cases overexpressed HER-2/neu at the protein level (IHC), and 11% of cases showed gene-amplification by MLPA. A high concordance was found between FISH and CISH, MLPA and IHC, and MLPA and CISH. MLPA showed amplification in 7/36 (19%) of the equivocal IHC 2+ cases. However, of the IHC 0/1+ cases, 6/434 (1.4%) were also amplified by MLPA, and amplification was confirmed in all of these cases by FISH/CISH. On the other hand, one of the 48 (2%) IHC 3+ cases was normal by MLPA and lack of amplification was confirmed by FISH/CISH. Conclusion: MLPA is a fast, accurate and cheap method to detect breast cancer HER-2/neu amplification in small quantities of DNA extracted from paraffin blocks, and thereby a reliable alternative to FISH and CISH.

[1]  M. Owens,et al.  HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. , 2004, Clinical breast cancer.

[2]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[3]  J. R. Reeves,et al.  Evaluating HER2 amplification and overexpression in breast cancer , 2001, The Journal of pathology.

[4]  D. Larsimont,et al.  Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. , 2000, The American journal of pathology.

[5]  J. Savulescu,et al.  No consent should be needed for using leftover body material for scientific purposes , 2002, BMJ : British Medical Journal.

[6]  K. Kwok,et al.  Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm , 2006, Modern Pathology.

[7]  T. Yamamoto,et al.  The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. , 1986, Science.

[8]  A. Lebeau.  HER2 Testing in Breast Cancer: Opportunities and Challenges , 2006, Breast Care.

[9]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[10]  W. Hanna,et al.  Chromogenic in-situ hybridisation compared with FISH and IHC for detection of HER2 gene amplification An international validation ring Study , 2003 .

[11]  Lajos Pusztai,et al.  Targeted Therapy in Breast Cancer , 2004, Molecular & Cellular Proteomics.

[12]  C. Zuiani,et al.  Large core biopsy for diagnostic and prognostic evaluation of invasive breast carcinomas. , 1996, European journal of cancer.

[13]  P. V. van Diest,et al.  Radiofrequency ablation for breast cancer: a review of the literature. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[14]  D. Visscher,et al.  Determination of Her-2/Neu Status in Breast Carcinoma: Comparative Analysis of Immunohistochemistry and Fluorescent In Situ Hybridization , 2000, Modern Pathology.

[15]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[16]  M. Gnant,et al.  Prognostic markers in breast cancer: the reliability of HER2/neu status in core needle biopsy of 325 patients with primary breast cancer , 2004, Wiener Klinische Wochenschrift.

[17]  James N Ingle,et al.  HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. , 2002, Mayo Clinic proceedings.

[18]  Z. Nemes,et al.  Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practice. , 2006, American journal of clinical pathology.

[19]  A. Au,et al.  Determination of HER2 Gene Amplification by Chromogenic In Situ Hybridization (CISH) in Archival Breast Carcinoma , 2002, Modern Pathology.

[20]  A. Hanby,et al.  Testing for HER2 in breast cancer , 2004, Histopathology.

[21]  M. Kraus,et al.  Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. , 1989, Genomics.

[22]  C. Hudis.  Trastuzumab--mechanism of action and use in clinical practice. , 2007, The New England journal of medicine.

[23]  L. Holmberg,et al.  Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  P. V. van Diest.  No consent should be needed for using leftover body material for scientific purposes. For. , 2002, BMJ.

[25]  R. Mass.  The role of HER-2 expression in predicting response to therapy in breast cancer. , 2000, Seminars in oncology.

[26]  R. Ridolfi,et al.  HER-2/neu Testing in Breast Carcinoma: A Combined Immunohistochemical and Fluorescence In Situ Hybridization Approach , 2000, Modern Pathology.

[27]  Miss A.O. Penney.  (b) , 1974, The New Yale Book of Quotations.

[28]  Lyndsay N Harris,et al.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  M. Mayo,et al.  A comparison of prognostic tumor markers obtained on image-guided breast biopsies and final surgical specimens. , 2002, American journal of surgery.

[30]  G. Reynolds,et al.  Demystified … , 2000 .

[31]  P. V. van Diest,et al.  Effects of chemotherapy on pathologic and biologic characteristics of locally advanced breast cancer. , 1997, American journal of clinical pathology.

[32]  J. Forteza,et al.  HER-2 status determination in breast carcinomas. A practical approach. , 2006, Histology and histopathology.

[33]  D. Slamon,et al.  Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. , 1994, Cancer research.

[34]  C. Marth,et al.  Immunohistochemical determination of her2 expression in breast cancer from core biopsy specimens: a reliable predictor of her2 status of the whole tumor , 2001, Breast Cancer Research and Treatment.

[35]  S. Schnitt,et al.  Do prognostic marker studies on core needle biopsy specimens of breast carcinoma accurately reflect the marker status of the tumor? , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[36]  T. Grogan,et al.  Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2007, Archives of pathology & laboratory medicine.

[38]  O. Dietze,et al.  Chromogenic In Situ Hybridization: A Novel Approach to a Practical and Sensitive Method for the Detection of HER2 Oncogene in Archival Human Breast Carcinoma , 2002, Laboratory Investigation.

[39]  G. Sauter,et al.  Close association between HER-2 amplification and overexpression in human tumors of non-breast origin , 2007, Modern Pathology.

[40]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[41]  M. Vijver,et al.  Correlation of chromogenic in-situ hybridisation (CISH) with FISH and IHC for assessment of HER2 gene amplification: an international validation ring study , 2004 .

[42]  M. Untch,et al.  Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  T. Stephenson,et al.  HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques , 2005, Journal of Clinical Pathology.

[44]  M. Dowsett,et al.  Current Perspectives on HER2 Testing: A Review of National Testing Guidelines , 2003, Modern Pathology.

[45]  H. Sasano,et al.  Reliability of prognostic factors in breast carcinoma determined by core needle biopsy. , 2007, Japanese journal of clinical oncology.

[46]  A. Gown,et al.  Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[48]  D. Zwijnenburg,et al.  Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. , 2002, Nucleic acids research.

[49]  H Buerger,et al.  Demystified … Tissue microarray technology , 2003, Molecular pathology : MP.

[50]  M. Fernö,et al.  ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. , 1994, Cancer letters.

[51]  G. Pals,et al.  Comparison of multiplex ligation dependent probe amplification to immunohistochemistry for assessing HER-2/neu amplification in invasive breast cancer , 2006, Biotechnic & histochemistry : official publication of the Biological Stain Commission.

[52]  D. Slamon,et al.  Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  J. Brisson,et al.  p53 and c-erbB-2 as markers of resistance to adjuvant chemotherapy in breast cancer. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[54]  A. Bianco,et al.  c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  N. Sneige,et al.  Reliability of chromogenic in situ hybridization for detecting HER-2 gene status in breast cancer: comparison with fluorescence in situ hybridization and assessment of interobserver reproducibility , 2005, Modern Pathology.

[56]  Jorma Isola,et al.  Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. , 2006, The New England journal of medicine.

[57]  A. V. D. van den Brule,et al.  Detection of HER2 Amplification in Breast Carcinomas: Comparison of Multiplex Ligation-Dependent Probe Amplification (MLPA) and Fluorescence In Situ Hybridization (FISH) combined with Automated Spot Counting , 2006, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[58]  E. Balslev,et al.  Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes , 2004, Acta oncologica.